Background: To evaluate the effect of Ozurdex® on intraocular pressure in patients with macular edema alone (group 1) or associated with glaucoma or ocular hypertension (group 2). Methods: A clinical, retrospective, observational, comparative study included 92 eyes with macular edema treated with a single injection of Ozurdex®; 27 eyes were previously diagnosed with glaucoma or ocular hypertension. Results: The mean intraocular pressure (group 1 vs. group 2) after injection was 12.1 versus 19.9 mm Hg, (p < 0.05; day 1); 17.5 versus 19.7 mm Hg (p < 0.05; month 1); 18.4 versus 20.9 mm Hg (p < 0.05; month 2); 15 versus 17.4 mm Hg (p < 0.05; month 3); 13.9 versus 16.7 mm Hg (p > 0.05; month 6); 13.8 versus 15.1 mm Hg (p > 0.05; month 9) and 13.1 versus 16.4 mm Hg (p > 0.05; month 12). Thirty eyes (32.6%) showed ocular hypertension (intraocular pressure >21 mm Hg) after the injection: 21.5% of group 1 and 59.3% of group 2. In group 2, 27 eyes (100%) needed medical treatment to reduce intraocular pressure in comparison to 8 patients (12.3%) in group 1 (p < 0.001). Conclusions: Intravitreal injection of Ozurdex® was associated with ocular hypertension in 32.6% of the eyes. Previous glaucoma or ocular hypertension are risk factors for this increase.

1.
Urban RC Jr, Dreyer EB: Corticosteroid-induced glaucoma. Int Ophthalmol Clin 1993;33:135-139.
2.
Armaly MF, Becker B: Intraocular pressure response to topical corticosteroids. Fed Proc 1965;24:1274-1278.
3.
Becker B: Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965;4:198-205.
4.
Armaly MF: Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482-491.
5.
Armaly MF: Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol 1963;70:492-499.
6.
Becker B, Hahn KA: Topical corticosteroids and heredity in primary open-angle glaucoma. Am J Ophthalmol 1964;57:543-551.
7.
Lam DSC, Fan DSP, Ng JS, et al: Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Experiment Ophthalmol 2005;33:252-258.
8.
Becker B: Diabetes mellitus and primary open-angle glaucoma: the XXVII Edward Jackson Memorial Lecture. Am J Ophthalmol 1971;71:1-16.
9.
Podos SM, Becker B, Morton WR: High myopia and primary open-angle glaucoma. Am J Ophthalmol 1966;62:1039-1043.
10.
Gaston H, Absolon MJ, Thurtie OA, et al: Steroid responsiveness in connective tissue diseases. Br J Ophthalmol 1983;67:487-490.
11.
Spaeth GL: Traumatic hyphema, angle recession, dexamethasone hypertension, and glaucoma. Arch Ophthalmol 1967;78:714-721.
12.
Becker B, Mills DW: Corticosteroids and intraocular pressure. Arch Ophthalmol 1963;70:500-507.
13.
Becker B, Mills DW: Elevated intraocular pressure following corticosteroid eye drops. JAMA 1963;185:884-886.
14.
François J, Heintz-De Bree C, Tripathi RC: The cortisone test and the heredity of early open-angle glaucoma (in French). Bull Soc Belge Ophthalmol 1965;141:576-581.
15.
Baath J, Ells AL, Crichton A, et al: Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther 2007;23:304-310.
16.
Roth DB, Verma V, Realini T, et al: Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology 2009;116:455-460.
17.
Ozkiriş A, Erkiliç K: Complications of intravitreal triamcinolone acetonide. Can J Ophthalmol 2005;40:63-68.
18.
Jonas JB, Degenring RF, Kreissig I, et al: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598.
19.
Kersey JP, Broadway DC: Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond) 2006;20:407-416.
20.
Carnaham MC, Goldstein DA: Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000;11:478-483.
21.
Lam DS, Kwok AKH, Chew S: Accelerated ocular hypertensive response to topical steroids in children. Br J Ophthalmol 1997;81:422-423.
22.
Tripathi RC, Parapuram SK, Tripathi BJ, et al: Corticosteroids and glaucoma risk. Drugs Aging 1999;15:439-450.
23.
Smithen LM, Ober MD, Maranan L, et al: Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-743.
24.
Herschler J: Intractable intraocular hypertension induced by repository triamcinolone acetonide. Am J Ophthalmol 1972;74:501-504.
25.
Helm CJ, Holland GN: The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995;120:55-64.
26.
Kalina RE: Increased intraocular pressure following subconjunctival corticosteroid administration. Arch Ophthalmol 1969;81:78-790.
27.
Jones R 3rd, Rhee DJ: Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006;17:163-167.
28.
Schindler RH, Chandler D, Thresher R, et al: The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417.
29.
Iwao K, Inatani M, Kawaji T, et al: Frequency and risk factors for intraocular pressure elevation after posterior sub-Tenon capsule triamcinolone acetonide injection. J Glaucoma 2007;16:251-256.
30.
European Glaucoma Society: Classification and Terminology. Terminology and Guidelines for Glaucoma, ed 4. Savona, PubliComm, 2014, chapt 2.2.6, pp 88-89.
31.
Haller JA, Bandello F, Belfort R Jr, et al; OZURDEX GENEVA Study Group: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134.e3-1146.e3.
32.
Meyer LM, Schönfeld CL: Secondary glaucoma after intravitreal dexamethasone 0.7 mg implant in patients with retinal vein occlusion: a one-year follow-up. J Ocul Pharmacol Ther 2013;29:560-565.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.